Corvus Pharmaceuticals (CRVS) vs. Albany Molecular Research (AMRI) Head-To-Head Survey
Corvus Pharmaceuticals (NASDAQ: CRVS) and Albany Molecular Research (NASDAQ:AMRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.
Insider and Institutional Ownership
83.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 72.1% of Albany Molecular Research shares are held by institutional investors. 14.5% of Albany Molecular Research shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Corvus Pharmaceuticals has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. Comparatively, Albany Molecular Research has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Corvus Pharmaceuticals and Albany Molecular Research, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Albany Molecular Research||0||4||0||0||2.00|
Corvus Pharmaceuticals presently has a consensus price target of $21.67, suggesting a potential upside of 33.33%. Albany Molecular Research has a consensus price target of $18.00, suggesting a potential downside of 17.20%. Given Corvus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than Albany Molecular Research.
This table compares Corvus Pharmaceuticals and Albany Molecular Research’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Albany Molecular Research||-5.93%||-13.39%||-3.42%|
Earnings & Valuation
This table compares Corvus Pharmaceuticals and Albany Molecular Research’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Corvus Pharmaceuticals||N/A||N/A||-$52.36 million||($2.58)||-6.30|
|Albany Molecular Research||$680.81 million||1.33||$73.33 million||($1.80)||-12.08|
Albany Molecular Research has higher revenue and earnings than Corvus Pharmaceuticals. Albany Molecular Research is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Albany Molecular Research beats Corvus Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
About Albany Molecular Research
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.